



COMPANY OVERVIEW

Oragenics, Inc. is focused on developing effective treatments for oral mucositis and becoming a leader in developing novel antibiotics against infectious diseases. Oragenics, Inc. has established exclusive worldwide channel collaborations with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases.

RECENT NEWS

Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

Mar 9 2021, 7:00 AM EST

STOCK OVERVIEW

Symbol	OGEN
Exchange	NYSE American
Market Cap	82.67m
Last Price	\$0.754
52-Week Range	\$0.37 - \$2.09

04/14/2021 04:00 PM EDT

INVESTOR RELATIONS

LHA Investor Relations
Kim Golodetz
Senior Vice President, Principal
T: 212-838-3777
kgolodetz@lhai.com

MANAGEMENT TEAM

Alan Joslyn, Ph.D.
President and Chief Executive Officer

Michael Sullivan
Chief Financial Officer

Dr. Martin Handfield
Senior Vice President of Discovery Research

ORAGENICS, INC.

4902 Eisenhower Blvd.
Suite 125
Tampa, FL 33634
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.